← Back to Search

Protease Inhibitor

Ritonavir + Agenerase for HIV

N/A
Waitlist Available
Research Sponsored by Gathe, Joseph, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have failed a previous anti-HIV treatment containing nelfinavir as the only protease inhibitor
Patients must have had more than 12 weeks of prior anti-HIV drug treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will test if a new anti-HIV drug is safe and can lower the level of HIV in the blood in patients who have failed another anti-HIV drug treatment.

Who is the study for?
This trial is for adults over 18 with HIV who've had more than 12 weeks of prior anti-HIV treatment and didn't respond to a regimen containing nelfinavir. Participants must have an HIV viral load above 1,000 copies/ml and be responsive to Agenerase. It's not for those with liver or pancreatic disease, absorption issues, certain medication use, previous Agenerase treatment, or women who are pregnant/breastfeeding.Check my eligibility
What is being tested?
The study tests the safety and effectiveness of a combination anti-HIV drug therapy using ritonavir and Agenerase in patients whose previous treatments failed. The goal is to see if this combo can reduce the amount of HIV in the blood.See study design
What are the potential side effects?
Potential side effects may include gastrointestinal issues like nausea or diarrhea, liver toxicity, allergic reactions, changes in body fat distribution (lipodystrophy), increased cholesterol levels, numbness or tingling sensations (neuropathy), and possible resistance to the drugs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have tried an HIV treatment with nelfinavir and it didn't work.
Select...
I have been on HIV medication for more than 12 weeks.
Select...
I am 18 years old or older.
Select...
I respond well to Agenerase medication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Gathe, Joseph, M.D.Lead Sponsor

Media Library

Agenerase (Protease Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00006591 — N/A
Human Immunodeficiency Virus Infection Research Study Groups:
Human Immunodeficiency Virus Infection Clinical Trial 2023: Agenerase Highlights & Side Effects. Trial Name: NCT00006591 — N/A
Agenerase (Protease Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006591 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this trial encompass individuals over twenty years of age?

"This clinical trial is restricted to individuals aged between 18 and 65 years old. Additionally, there are 108 studies that accept patients younger than 18 and 352 for those older than 65."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment
2024. "Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00006591.
All > Hiv Infection
~233 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top